BIOMAT Database Logo BIOMAT Database Logo

Murine spontaneous T-cell leukemia constitutively expressing IL-2 receptor--a model for human T-cell malignancies expressing IL-2 receptor. 1990

H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
Lautenberg Center for General and Tumor Immunology, Hebrew University-Hadassah Medical School, Jerusalem, Israel.

We describe a new, spontaneously occurring BALB/c-derived murine T-cell leukemia. The leukemic cells, designated LB, grow rapidly and progressively in the syngeneic host with no signs of effective immunological resistance. LB cells expressed the Thy-1+, Lyt-2+, L3T4-, CD3- class-I+, CD25+ (IL-2 receptor, IL-2R), class-II-, gp70- phenotype. As LB cells express IL-2, as indicated by staining with 2 distinct anti-CD25 IL-2R monoclonal antibodies (MAbs), the therapeutic efficacy of IL-2-diphtheria toxin-related protein was tested on this leukemic model. IL-2-diphtheria toxin, but not diphtheria toxin, efficiently inhibited the proliferation of LB cells. The proliferation of a murine myeloma cell line, which does not express IL-2R, was not inhibited by IL-2-diphtheria toxin. The possible implantation of this animal model in fundamental and practical studies is discussed.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D004167 Diphtheria Toxin An ADP-ribosylating polypeptide produced by CORYNEBACTERIUM DIPHTHERIAE that causes the signs and symptoms of DIPHTHERIA. It can be broken into two unequal domains: the smaller, catalytic A domain is the lethal moiety and contains MONO(ADP-RIBOSE) TRANSFERASES which transfers ADP RIBOSE to PEPTIDE ELONGATION FACTOR 2 thereby inhibiting protein synthesis; and the larger B domain that is needed for entry into cells. Corynebacterium Diphtheriae Toxin,Toxin, Corynebacterium Diphtheriae
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females

Related Publications

H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
Internalization of IL-2 by an IL-2-dependent murine T cell lymphoma expressing no detectable cell surface receptors for IL-2.
June 1988, Leukemia,
H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia.
December 2021, Science translational medicine,
H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
IL-2 receptor dysfunction and adult T-cell leukemia.
August 1986, Immunological reviews,
H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
Spontaneous T cell antigen receptor variants of a human T leukemia cell line.
November 1988, Journal of immunology (Baltimore, Md. : 1950),
H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
IL-2 receptors on rabbit T-cell lines and their transfectants expressing the human IL-2 receptor alpha chain.
December 1990, Immunology,
H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
T cells expressing IL-2 receptor in migraine.
October 1991, Acta neurologica,
H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
T cell malignancies and human T cell leukemia virus.
March 1984, Seminars in oncology,
H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
The murine IL 2 receptor. III. Cellular requirements for the induction of IL 2 receptor expression on T cell subpopulations.
April 1985, Journal of immunology (Baltimore, Md. : 1950),
H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
AKR T-cell acute lymphoblastic leukemia: a model for human T-cell leukemia.
October 1977, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
H Lugasi, and S Hajos, and J R Murphy, and T B Strom, and J Nichols, and C Peñarroja, and D Naor
Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies.
August 2023, Cells,
Copied contents to your clipboard!